加载中
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
前收盘价
US$23.33
+US$0.58 · +2.55%
盘中时间采用ET。市场数据可能有所延迟。
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
日内区间
当前US$23.33
52周区间
当前US$23.33
盘中时间采用ET。市场数据可能有所延迟。
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
日内区间
当前US$23.33
52周区间
当前US$23.33
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 6348.9万 USD | 4136.4万 USD | 3696.6万 USD | 2565.4万 USD | 1097.7万 USD |
| 销售、一般及管理费用 | 2054.7万 USD | 1665.1万 USD | 768.2万 USD | 717.6万 USD | 463.3万 USD |
| 营业费用 | 8403.6万 USD | 5801.5万 USD | 4464.8万 USD | 3283万 USD | 1561万 USD |
| 利息收入 | 1129.7万 USD | 426.1万 USD | 58.1万 USD | 14.9万 USD | — |
| 利息支出 | 6.3万 USD | 10.7万 USD | 15.2万 USD | 14.4万 USD | 22.4万 USD |
| 折旧和摊销 | 137.5万 USD | 164.5万 USD | 147.8万 USD | 100.6万 USD | 36.4万 USD |
| 营业利润 | −8403.6万 USD | −5801.5万 USD | −4464.8万 USD | −3283万 USD | −1561万 USD |
| 净利润 | −7415.1万 USD | −5798.2万 USD | −4282.3万 USD | −3218万 USD | −892.7万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$78.67
上涨空间 237.21%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM625.35万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO176.52万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB166.22万0.02%108.2亿 USD0.44%US$206.49+3.00%
iShares Micro-Cap ETFIWC78.63万0.06%13.17亿 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT77.07万0.00%220亿 USD0.09%US$319.01+1.64%
ALPS Medical Breakthroughs ETFSBIO57.89万0.30%1.91亿 USD0.50%US$55.04+2.03%
Avantis U.S. Small Cap Equity ETFAVSC49.9万0.02%30.82亿 USD0.25%US$69.98+0.03%
iShares Russell 2000 Growth ETFIWO44.28万0.00%139.17亿 USD0.24%US$356.78+0.94%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
